Vectored delivery of anti-SIV envelope targeting mAb via AAV8 protects rhesus macaques from repeated limiting dose intrarectal swarm SIVsmE660 challenge
Open accessThe DOI matches its Crossref record; 72 of the 73 references it cites were found in a registry or an index.
Abstract
Gene based delivery of immunoglobulins promises to safely and durably provide protective immunity to individuals at risk of acquiring infectious diseases such as HIV. We used a rhesus macaque animal model to optimize delivery of naturally-arising, autologous anti-SIV neutralizing antibodies expressed by Adeno-Associated Virus 8 (AAV8) vectors. Vectored transgene expression was confirmed by quantitation of target antibody abundance in serum and mucosal surfaces. We tested the expression achieved at varying doses and numbers of injections. Expression of the transgene reached a saturation at about 2 x 10(12) AAV8 genome copies (gc) per needle-injection, a physical limitation that may not scale clinically into human trials. In contrast, expression increased proportionately with the number of injections. In terms of anti-drug immunity, anti-vector antibody responses were universally strong, while those directed against the natural transgene mAb were detected in only 20% of animals. An anti-transgene antibody response was invariably associated with loss of detectable plasma expression of the antibody. Despite having atypical glycosylation profiles, transgenes derived from AAV-directed muscle cell expression retained full functional activity, including mucosal accumulation, in vitro neutralization, and protection against repeated limiting dose SIVsmE660 swarm challenge. Our findings demonstrate feasibility of a gene therapy-based passive immunization strategy against infectious disease, and illustrate the potential for the nonhuman primate model to inform clinical AAV-based approaches to passive immunization.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures







Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In one study, re-administration of AAV8 in NHP did not result in increased transgene expression, but increased anti-AAV antibody levels were observed [75].”
From Immunogenicity of Recombinant Adeno-Associated Virus (AAV) Vectors for Gene Transfer (2023) · cites this paper as [75]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Manno, C. S., Pierce, G. F., Arruda, V. R., Glader, B., Ragni, M., Rasko, J. J. E., Ozelo, M. C., Hoots, K., Blatt, P., Konkle, B., et al. (2006) · Nature Medicine · doi:10.1038/nm1358 · Cited by 2,163
Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's Disease
Baert, F., Noman, M., Vermeire, S., Van Assche, G., D' Haens, G., Carbonez, A., & Rutgeerts, P. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa020888 · Cited by 2,015
Adenovirus-Associated Virus Vector–Mediated Gene Transfer in Hemophilia B
Nathwani, A. C., Tuddenham, E. G. D., Rangarajan, S., Rosales, C., McIntosh, J., Linch, D. C., Chowdary, P., Riddell, A., Pie, A. J., Harrington, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1108046 · Cited by 1,864
Long-Term Safety and Efficacy of Factor IX Gene Therapy in Hemophilia B
Nathwani, A. C., Reiss, U. M., Tuddenham, E. G. D., Rosales, C., Chowdary, P., McIntosh, J., Della Peruta, M., Lheriteau, E., Patel, N., Raj, D., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407309 · Cited by 1,273
Beyond binding: antibody effector functions in infectious diseases
Lu, L. L., Suscovich, T. J., Fortune, S. M., & Alter, G. (2018) · Nature Reviews Immunology · doi:10.1038/nri.2017.106 · Cited by 825
Self-citationHemophilia B Gene Therapy with a High-Specific-Activity Factor IX Variant
George, L. A., Sullivan, S. K., Giermasz, A., Rasko, J. E. J., Samelson-Jones, B. J., Ducore, J., Cuker, A., Sullivan, L. M., Majumdar, S., Teitel, J., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1708538 · Cited by 762
AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B
Manno, C. S., Chew, A. J., Hutchison, S., Larson, P. J., Herzog, R. W., Arruda, V. R., Tai, S. J., Ragni, M. V., Thompson, A., Ozelo, M., et al. (2003) · Blood · doi:10.1182/blood-2002-10-3296 · Cited by 749
AAV5–Factor VIII Gene Transfer in Severe Hemophilia A
Rangarajan, S., Walsh, L., Lester, W., Perry, D., Madan, B., Laffan, M., Yu, H., Vettermann, C., Pierce, G. F., Wong, W. Y., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1708483 · Cited by 694
Industrialization of mAb production technology: The bioprocessing industry at a crossroads
Kelley, B. (2009) · mAbs · doi:10.4161/mabs.1.5.9448 · Cited by 667
Evaluating Neutralizing Antibodies Against HIV, SIV, and SHIV in Luciferase Reporter Gene Assays
Montefiori, D. C. (2004) · Current Protocols in Immunology · doi:10.1002/0471142735.im1211s64 · Cited by 580
Research works printed but not linked: 2
- D Gaudet, 2013, Efficacy and long-term safety of alipogene tiparvovec (AAV1-LPLS447X) gene therapy for lipoprotein lipase deficiency: an open-label trial, Gene Ther. Macmillan Publishers Limited, 20, 361
- KO Saunders, 2015, Sustained Delivery of a Broadly Neutralizing Antibody in Nonhuman Primates Confers Long-Term Protection against Simian/Human Immunodeficiency Virus Infection, J Virol, 89, 5895, 10.1128/JVI.00210-15 · DOI · Paper page
Cited by
Immunogenicity of Recombinant Adeno-Associated Virus (AAV) Vectors for Gene Transfer
Arjomandnejad, M., Dasgupta, I., Flotte, T. R., & Keeler, A. M. (2023) · BioDrugs · doi:10.1007/s40259-023-00585-7 · Cited by 159
“In one study, re-administration of AAV8 in NHP did not result in increased transgene expression, but increased anti-AAV antibody levels were observed [75].”
BackgroundPegu, A., Borate, B. R., Huang, Y., Pauthner, M. G., Hessell, A. J., Jülg, B. D., Doria‐Rose, N. A., Schmidt, S. D., Carpp, L. N., Cully, M. D., et al. (2019) · Cell Host & Microbe · doi:10.1016/j.chom.2019.08.014 · Cited by 122
Self-citationCasazza, J. P., Cale, E. M., Narpala, S., Yamshchikov, G. V., Coates, E. E., Hendel, C. S., Novik, L., Holman, L. A., Widge, A. T., Apte, P., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01762-x · Cited by 91
Self-citationAdvancements in mRNA Encoded Antibodies for Passive Immunotherapy
Deal, C. E., Carfí, A., & Plante, O. J. (2021) · Vaccines · doi:10.3390/vaccines9020108 · Cited by 91
“Dose escalation studies demonstrated increasing serum concentrations of ZIKV-117 as the dose escalated to 10 μg of mRNA, after which there was no significant increase, likely due to saturation of protein production from cells at the injection site and innate immune activation [85].”
BackgroundAAV-delivered eCD4-Ig protects rhesus macaques from high-dose SIVmac239 challenges
Gardner, M. R., Fellinger, C. H., Kattenhorn, L. M., Davis-Gardner, M. E., Weber, J. A., Alfant, B., Zhou, A. S., Prasad, N. R., Kondur, H. R., Newton, W. A., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aau5409 · Cited by 52
Self-citationLong-Term Delivery of an Anti-SIV Monoclonal Antibody With AAV
Martinez-Navío, J. M., Fuchs, S. P., Mendes, D. E., Rakasz, E. G., Gao, G., Lifson, J. D., & Desrosiers, R. C. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00449 · Cited by 51
Self-citationvan Lieshout, L. P., Soule, G., Sorensen, D., Frost, K. L., He, S., Tierney, K. J., Safronetz, D., Booth, S. A., Kobinger, G., Qiu, X., et al. (2017) · The Journal of Infectious Diseases · doi:10.1093/infdis/jix644 · Cited by 49
van den Berg, F. T., Aminake, M. N., Ali, S. A., Scott, T. A., Mapengo, R. E., Mutsvunguma, L. Z., Mkhize, N. N., Lambson, B. E., Kgagudi, P., Crowther, C. E., et al. (2019) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2019.06.002 · Cited by 47
Self-citationIn vivo delivery of synthetic DNA–encoded antibodies induces broad HIV-1–neutralizing activity
Wise, M. C., Xu, Z., Tello‐Ruiz, E., Beck, C., Trautz, A., Patel, A. R., Elliott, S. T. C., Chokkalingam, N., Kim, S., Kerkau, M., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci132779 · Cited by 50
“Furthermore, AAV delivery of fully rhesus monoclonal antibodies 266 against SIV led to a lower incidence of ADA responses in rhesus macaques (34).”
BackgroundBlocking α 4 β 7 integrin binding to SIV does not improve virologic control
Iwamoto, N., Mason, R. D., Song, K., Gorman, J., Welles, H. C., Arthos, J. A., Cicala, C., Min, S., King, H. A. D., Belli, A. J., et al. (2019) · Science · doi:10.1126/science.aaw7765 · Cited by 36
Self-citationFuchs, S. P., Martinez-Navio, J. M., Rakasz, E. G., Gao, G., & Desrosiers, R. C. (2020) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2019.11.010 · Cited by 32
Zhan, W., Muhuri, M., Tai, P. W. L., & Gao, G. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.673699 · Cited by 37
“ADAs can appear as early as two weeks post-AAV transduction and animals with higher levels of ADAs usually present with lower levels of therapeutic mAbs in the blood stream (71, 87, 88).”
BackgroundInfluentialGardner, M. R., Mendes, D. E., Muniz, C. P., Martinez-Navio, J. M., Fuchs, S. P., Gao, G., & Desrosiers, R. C. (2022) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2022.01.003 · Cited by 30
“An antiAAV response after inoculation typically limits the transduction of a second inoculation with that same AAV capsid.(16) For this study, we used 12 rhesus macaque samples from a previous study.”
MethodGardner, M. R. (2020) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2020.00176 · Cited by 31
Chung, C. W., Kudchodkar, S. B., Chung, C. N., Park, Y. K., Xu, Z., Pardi, N., Abdel‐Mohsen, M., & Muthumani, K. (2023) · Antibodies · doi:10.3390/antib12030046 · Cited by 40
“Cellular immune responses against AAV capsid limit transgene expression by eliminating transduced cells [47].”
BackgroundBrady, J. M., Phelps, M., MacDonald, S. W., Lam, E. C., Nitido, A. D., Parsons, D., Boutros, C. L., Deal, C. E., García-Beltrán, W. F., Tanno, S., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abn9662 · Cited by 25
Self-citationPagant, S., & Liberatore, R. A. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13111882 · Cited by 22
Phelps, M., & Balazs, A. B. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.734304 · Cited by 22
“Importantly, they observed anti-drug antibody responses in many of the participants of the study, suggesting that these may have limited the potential for PG9 expression (113).”
BackgroundSelf-citationGoldeck, D., Perry, D., Hayes, J. W. P., Johnson, L. P. M., Young, J. E., Roychoudhury, P., McLuskey, E. L., Moffat, K., Bakker, A. Q., Kwakkenbos, M. J., et al. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00572 · Cited by 17
Welles, H. C., King, H. A. D., Nettey, L., Cavett, N., Gorman, J., Zhou, T., Tsybovsky, Y., Du, R., Song, K., Nguyen, R., et al. (2022) · PLoS Pathogens · doi:10.1371/journal.ppat.1010574 · Cited by 17
“We also isolated anti-idiotype mAbs specific for firstgeneration SIV V2-specific nAbs ITS09 and ITS12 [12] which have been of particular interest for NHP mAb studies [69,70] owing to the strong correlation between IgG Env V1V2-binding antibody levels and the modest efficacy observed in the RV144 Phase III vaccine tria…”
BackgroundSelf-citationGrunst, M. W., Grandea, A. G., Janaka, S. K., Hammad, I., Grimes, P., Karl, J. A., Wiseman, R. W., O’Connor, D. H., & Evans, D. T. (2020) · The Journal of Immunology · doi:10.4049/jimmunol.2000501 · Cited by 16
Rghei, A. D., van Lieshout, L. P., Cao, W., He, S., Tierney, K. J., Lopes, J. A., Zielinska, N., Baracuhy, E. M., Campbell, E. S. B., Minott, J. A., et al. (2022) · Gene Therapy · doi:10.1038/s41434-022-00361-2 · Cited by 16
“Withafew exceptions [62], analysis of AAV VIP in NHPs and humans has primarily been conducted using HIV bNAbs.”
Tebas, P., Patel, A. R., Agnes, J. T., Parzych, E. M., Baer, A. L., Caturla, M., Ghosh, S., Purwar, M., Bedanova, N. M., Tsang, C., et al. (2025) · Nature Medicine · doi:10.1038/s41591-025-03969-0 · Cited by 18
“Interestingly, delivering the same total dose across four injection sites resulted in substantially greater expression than delivering it at one site, which is consistent with findings from AAV studies showing spatial limitations to delivery 19 .”
A strategy for high antibody expression with low anti-drug antibodies using AAV9 vectors
Davis-Gardner, M. E., Weber, J. A., Xie, J., Pekrun, K., Alexander, E. A., Weisgrau, K. L., Furlott, J. R., Rakasz, E. G., Kay, M. A., Gao, G., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1105617 · Cited by 16
“AAV8, and AAV9 – along with two engineered capsids – AAVNP22 and AAV-KP1 – for expression of the anti-SIV antibody, ITS01 (15), after i.”
BackgroundResultInfluentialGrunst, M. W., Ladd, R. A., Clark, N. M., Gil, H. M., Klenchin, V. A., Mason, R. D., Franchini, G., Roederer, M., & Evans, D. T. (2023) · PLoS Pathogens · doi:10.1371/journal.ppat.1011407 · Cited by 15
“Antibodies isolated from rhesus macaques also induce much lower anti-drug antibody (ADA) responses than human or “simianized” antibodies when administered to macaques [35,47], which is essential for studies designed to achieve sustained antibody concentrations in vivo [25,35,47–50].”
InfluentialSelf-citationPathak, S., Singh, V., Kumar, N., & Jayandharan, G. R. (2023) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2023.101166 · Cited by 15
“42 Although we noticed high AAV transduction in the mutant group, the same does not get re fl ected in terms of RTV, and we speculate that this discrepancy may stem from the limited availability of the dimerizer drug AP20187, which is integral to the ultimate cell kill effect.”
BackgroundHahn, P. A., & Martins, M. A. (2023) · Journal of Virus Eradication · doi:10.1016/j.jve.2023.100316 · Cited by 15
Antibody prophylaxis may mask subclinical SIV infections in macaques
Gonelli, C. A., King, H. A. D., Ko, S., Fennessey, C. M., Iwamoto, N., Mason, R. D., Heimann, A., Flebbe, D. R., Todd, J.-P. M., Foulds, K. E., et al. (2025) · Nature · doi:10.1038/s41586-024-08500-y · Cited by 13
“1) The authors consistently use the terms “fully” or “partially” neutralizing when describing the mAbs used in this study, but there is no clear description of what those terms define.”
Self-citationCrowley, A. R., Osei‐Owusu, N. Y., Dekkers, G., Gao, W., Wuhrer, M., Magnani, D. M., Reimann, K. A., Pincus, S. H., Vidarsson, G., & Ackerman, M. E. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.754710 · Cited by 13
“These results have important implications for the use of RM to study recombinant glycoengineered antibodies in preclinical and mechanistic studies of antibody therapies, as well as in attempting to relate antibody glycotypes raised in response to vaccination (60–62) or via vectored antibody delivery (63), to in vitro…”
BackgroundVectored antibody gene delivery restores host B and T cell control of persistent viral infection
Ertuna, Y. I., Fallet, B., Marx, A., Dimitrova, M., Kastner, A. L., Wagner, I., Merkler, D., & Pinschewer, D. D. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.110061 · Cited by 8
Li, S., Qiao, Y., Jiang, S., Wang, B., Kong, W., & Shan, Y. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.09.006 · Cited by 10
Lopes, J. A., Garnier, N. E., Pei, Y., Yates, J. G. E., Campbell, E. S. B., Goens, M. M., Hughes, M. E., Rghei, A. D., Stevens, B. A. Y., Guilleman, M. M., et al. (2024) · Gene Therapy · doi:10.1038/s41434-024-00453-1 · Cited by 9
“…mAb genes, also known as AAV-vectored immunoprophylaxis (AAV-VIP), has been shown to protect against a wide variety of infectious diseases [25 – 28] in a range of animal models, including nonhuman primates [29], and is now being tested in two human clinical trials for human immunode fi ciency virus.”
Klenchin, V. A., Clark, N. M., Keles, N. K., Capuano, S., Mason, R. D., Gao, G., Broman, A. T., Köse, E., Immonen, T. T., Fennessey, C. M., et al. (2025) · Science Immunology · doi:10.1126/sciimmunol.adq4973 · Cited by 10
Self-citationRghei, A. D., van Lieshout, L. P., McLeod, B. M., Pei, Y., Lopes, J. A., Zielinska, N., Baracuhy, E. M., Stevens, B. A. Y., Thomas, S. P., Yates, J. G. E., et al. (2021) · Biomedicines · doi:10.3390/biomedicines9091186 · Cited by 9
“6 μg/mL while providing protection from weekly limiting dose intrarectal SIV challenges [27].”
BackgroundRecent Advancements in AAV-Vectored Immunoprophylaxis in the Nonhuman Primate Model
Campbell, E. S. B., Goens, M. M., Cao, W., Thompson, B., Susta, L., Banadyga, L., & Wootton, S. K. (2023) · Biomedicines · doi:10.3390/biomedicines11082223 · Cited by 10
“02) were administered to rhesus macaques using an AAV8 vector [2].”
BackgroundMethodInfluentialZandt, A. R. V., & MacLean, A. G. (2023) · Journal of NeuroVirology · doi:10.1007/s13365-023-01162-y · Cited by 9
“2009), necessitating artificial delivery (Welles et al. 2018) or stimulation for assembly.”
BackgroundAdeno-associated viral vectors deliver gene vaccines
Wei, L., Yu, P., Wang, H., & Liu, J. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.117010 · Cited by 10
Fuchs, S. P., Mondragon, P. G., Zabizhin, R., Tomer, S., Wang, L., Cook, E., Dudley, D. M., Weisgrau, K. L., Furlott, J. R., Coonen, J., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-63970-6 · Cited by 10
“Other monkey trials 20,21 and the two human trials 22,23 investigating AAV delivery of anti-HIV bnAbs have also observed ADAs and little or no delivery of the desired bnAbs.”
Self-citationNicholas, R. E., Sandstrom, K., Anderson, J. L., Smith, W. R., Wetzel, M., Banerjee, P., Janaka, S. K., & Evans, D. T. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.841136 · Cited by 8
MHC Class I Ligands of Rhesus Macaque Killer Cell Ig-like Receptors
Anderson, J. L., Sandstrom, K., Smith, W. R., Wetzel, M., Klenchin, V. A., & Evans, D. T. (2023) · The Journal of Immunology · doi:10.4049/jimmunol.2200954 · Cited by 8
Progress in novel delivery technologies to improve efficacy of therapeutic antibodies
Sun, W., Wu, Y., & Ying, T. (2024) · Antiviral Research · doi:10.1016/j.antiviral.2024.105867 · Cited by 9
Shipulin, G. A., Glazkova, D. V., Урусов, Ф. А., Belugin, B. V., Dontsova, V., Panova, A. V., Borisova, A. A., Цыганова, Г. М., & Bogoslovskaya, E. V. (2024) · Viruses · doi:10.3390/v16081296 · Cited by 8
“Similar results were observed in a study by Welles et al. (2018) in rhesus monkeys, wherein the AAV8 vector encoding monoclonal antibodies against the simian immunodeficiency virus was injected into one or more sites [30].”
ResultIn pursuit of an HIV cure: from stem cell transplants to gene therapies
Clees, J., Basic, M., Cruz, P. E., Ramirez, S. H., & Andrews, A. M. (2025) · Frontiers in Genome Editing · doi:10.3389/fgeed.2025.1634193 · Cited by 5
Recent Advances Using Genetic Therapies Against Infectious Diseases and for Vaccination
Galy, A. H. M., Berkhout, B., Breckpot, K., Pichon, C., Bloom, K. M., Kiem, H., Mühlebach, M. D., & McCune, J. M. (2023) · Human Gene Therapy · doi:10.1089/hum.2023.123 · Cited by 4
“35 However, AAV-mediated mAb delivery is limited by the induction of an-tidrug antibodies (ADAs) for example, antibodies against the AAV-delivered bNab.”
Protection against SIV in Rhesus Macaques Using Albumin and CD4-Based Vector-Mediated Gene Transfer
Spitsin, S. V., Schnepp, B. C., Connell, M. J., Liu, T., Dang, C. M., Pappa, V., Tustin, R., Kinder, A., Johnson, P. R., & Douglas, S. D. (2020) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2020.04.019 · Cited by 2
Ko, H., Li, Y.-Y., Simanjuntak, Y., Yu, H.-P., Chiang, M., Lee, C.-Y., Liang, J., Lee, Y.-L., Sun, C., Wang, P.-S., et al. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.09.007 · Cited by 2
Synthetic serum markers enable noninvasive monitoring of gene expression in primate brains
Lee, S., Romac, M. D., Watanabe, S., Chernov, M. M., Li, H., Raisley, E. K., Rothenhoefer, K. M., Dahlquist, Z., Szablowski, J. O., & Costa, V. D. (2026) · Neuron · doi:10.1016/j.neuron.2026.01.003 · Cited by 3
Gálvez, N. M. S., Nitido, A. D., Yoo, S. B., Cao, Y., Deal, C. E., Boutros, C. L., MacDonald, S. W., Albrecht, Y. E. S., Lam, E. C., Sheehan, M. L., et al. (2026) · Immunity · doi:10.1016/j.immuni.2026.01.031 · Cited by 4
Self-citationMHC class I Ligands of Rhesus Macaque Killer-Cell Immunoglobulin-Like ReceptorsPreprint
Anderson, J. L., Sandstrom, K., Smith, W. R., Wetzel, M., Klenchin, V. A., & Evans, D. T. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.05.25.493479 · Cited by 2
“79 The rhesus macaque has become an increasingly valuable animal model for infectious 80 diseases (57-68), reproductive biology (44, 69), and transplantation (70, 71).”
BackgroundVectored long-term co-delivery of antibodies for SARS-CoV-2, RSV and Influenza prophylaxis
Nielsen, S. S. F., Rothemejer, F. H., Andreas, M., Pedersen, M. L., Traberg‐Nyborg, L., Iversen, E. F., Juhl, A. K., Søgaard, O. S., Schleimann, M. H., & Tolstrup, M. (2025) · Virology · doi:10.1016/j.virol.2025.110573 · Cited by 1
Xu, Z. (2020) · ScholarlyCommons (University of Pennsylvania)
Wang, Y. (2019) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.736249978.793563135
Manchester, B. J., Gommerman, J. L., Sharif, S., Susta, L., & Wootton, S. K. (2026) · Vaccines · doi:10.3390/vaccines14080692
“Additional experiments showed that animals with pre-existing immunity to AAV and re-dosed animals produced significant anti-capsid responses against administration [118].”
Influential
Metadata
- Authors
- Welles, H. C., Jennewein, M. F., Mason, R. D., Narpala, S., Wang, L., Cheng, C., Zhang, Y., Todd, J.-P., Lifson, J. D., Balazs, A. B., Alter, G., McDermott, A. B., Mascola, J. R., & Roederer, M.
- Affiliations
- National Institutes of Health (US)
- Ragon Institute of MGH, MIT and Harvard (US)
- Frederick National Laboratory for Cancer Research (US)
- Corresponding author
- Welles, Hugh C.
- Jennewein, Madeleine F.
- Mason, Rosemarie D.
- Narpala, Sandeep
- Wang, Lingshu
- Cheng, Cheng
- Zhang, Yi
- Todd, John-Paul
- Lifson, Jeffrey D.
- Balazs, Alejandro B.
- Alter, Galit
- McDermott, Adrian B.
- Mascola, John R.
- Roederer, Mario
- ORCID
- Venue
- PLOS Pathogens
- Publisher
- Public Library of Science (PLoS)
- Published
- 2018-12-05
- Volume
- 14
- Issue
- 12
- Pages
- e1007395
- ISSN
- 1553-7366 (ISSN-L)
- 1553-7374
- PMC
- PMC6296672
- OpenAlex
- W2902838323
- Cited by
- 53
- References
- 73
- Citations by year
- 2026: 3 · 2025: 7 · 2024: 4 · 2023: 10 · 2022: 7 · 2021: 8 · 2020: 5 · 2019: 8
- FWCI
- 3.22
- Type
- journal article
- Language
- en
- Update notices
- new_version (2018-12-17)
- Open access
- gold
- doi.org
- Licence
- public-domain
- creativecommons.org/publicdomain/zero/1.0/ (vor)
- Locations
- PLoS Pathogens (publishedVersion, public-domain)
- Europe PMC (PubMed Central) (publishedVersion, public-domain)
- PubMed Central (publishedVersion, public-domain)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- Funders
- U.S. Department of Health and Human Services
- Frederick National Laboratory for Cancer Research
- National Institutes of Health (HHSN261200800001C)
- National Institute on Drug Abuse (DP2DA040254)
- National Cancer Institute (HHSN261200800001E))
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Immunology and Microbiology › Virology › HIV Research and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Keywords
- AAV8 vector, gene therapy, passive immunization, rhesus monkeys, intrarectal challenge, HIV prevention, glycosylation, nonhuman primate model
- MeSH terms
- Dependovirus, Animals, Antibodies, Monoclonal, Antibodies, Viral, Genetic Vectors, Immunization, Passive, Macaca mulatta, Viral Envelope Proteins, Simian Immunodeficiency Virus, Genetic Therapy, Simian Acquired Immunodeficiency Syndrome, SAIDS Vaccines, Transgenes, Antibodies, Neutralizing
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.